发明名称 TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING
摘要 In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGFβR) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGFβR inhibitor. Further described herein are kits for producing iPS cells using a TGFβR inhibitor.
申请公布号 US2014120621(A1) 申请公布日期 2014.05.01
申请号 US201314062185 申请日期 2013.10.24
申请人 THE GENERAL HOSPITAL CORPORATION 发明人 HOCHEDLINGER KONRAD;STADTFELD MATTHIAS
分类号 C12N5/074 主分类号 C12N5/074
代理机构 代理人
主权项
地址